(Q46931630)

26 December 2017

title

Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation (English)

1 reference

26 December 2017

0 references

1 reference

4

1 reference

26 December 2017

author name string

A C Calkin

series ordinal

1

1 reference

26 December 2017

M E Cooper

series ordinal

2

1 reference

26 December 2017

K A Jandeleit-Dahm

series ordinal

3

1 reference

26 December 2017

publication date

4 February 2006

1 reference

26 December 2017

published in

Diabetologia

1 reference

26 December 2017

volume

49

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

page(s)

766-774

1 reference

26 December 2017

Mechanism of action of fibrates on lipid and lipoprotein metabolism

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

NAD(P)H oxidase: role in cardiovascular biology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0102-6

Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.

21 January 2018

1 reference

12 December 2020

Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products

1 reference

12 December 2020

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

1 reference

12 December 2020

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

1 reference

12 December 2020

Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB

1 reference

12 December 2020

Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

1 reference

12 December 2020

Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

1 reference

12 December 2020

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

1 reference

12 December 2020

Imatinib attenuates diabetes-associated atherosclerosis

1 reference

12 December 2020

Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia

1 reference

12 December 2020

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

1 reference

12 December 2020

Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B).

1 reference

12 December 2020

Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis

1 reference

12 December 2020

Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors

1 reference

12 December 2020

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects

1 reference

12 December 2020

Angiotensin II induces MMP-2 in a p47phox-dependent manner

1 reference

12 December 2020

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

1 reference

12 December 2020

Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases

1 reference

12 December 2020

The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells

1 reference

12 December 2020

Mechanical Stretch Enhances mRNA Expression and Proenzyme Release of Matrix Metalloproteinase-2 (MMP-2) via NAD(P)H Oxidase–Derived Reactive Oxygen Species

1 reference

12 December 2020

Induction of Tissue Factor Expression in Endothelial Cells by Basic Fibroblast Growth Factor and its Modulation by Fenofibric acid

1 reference

12 December 2020

The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E

1 reference

12 December 2020

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Tr

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells

1 reference

12 December 2020

Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages

1 reference

12 December 2020

Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation

1 reference

12 December 2020

Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study).

1 reference

12 December 2020

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

1 reference

12 December 2020

Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice

1 reference

12 December 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

12 December 2020

Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

12 December 2020

Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice

1 reference

12 December 2020

Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients

1 reference

12 December 2020

PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

1 reference

12 December 2020

Oxidative stress and diabetic vascular complications

1 reference

12 December 2020

10.1007/S00125-005-0102-6

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017